Dose-dense ABVD First Line Therapy in Early Stage Unfavorable Hodgkin's Lymphoma
Status:
Completed
Trial end date:
2017-04-29
Target enrollment:
Participant gender:
Summary
Prospective, multicenter, Phase II trial designed to assess whether intensification of ABVD
(dd-ABVD) is feasible and can improve the outcome of patients with early stage Hodgkin
Lymphoma.